A Phase 2/3 interventional study of Atacicept 75 mg and Atacicept 150 mg in Lupus Erythematosus, Systemic, sponsored by EMD Serono. Completed at 113 sites in 29 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-03-14.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany — 3 open to participants now, 4 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Merck KGaA, Darmstadt, Germany.
Among the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, this one is the 2nd largest by enrollment, is the only one that started in 2008, is the only one in phase 2/3, and was the 1st registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →3 of the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany are open now, in 12 countries. Recruiting first, the newest first:
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 4
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 461 is above the median of 52 across 879 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 280 across the 12 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the efficacy and safety of atacicept compared to placebo in preventing new flares in subjects with systemic lupus erythematosus (SLE) and to confirm the optimal dose of atacicept for treatment of subjects with SLE and gain information on the effect of atacicept on markers specific to its mechanism of action (MoA) and their correlation to disease activity/progression. Study medication will be administered through subcutaneous (under the skin) injections, beginning with twice weekly injections for the first 4 weeks, followed by once weekly doses for 48 weeks. Following the last treatment, a safety follow-up period of 24 weeks will be conducted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Atacicept 75 mg
Drug: Atacicept 150 mg
Other: Placebo Comparator
75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or B
A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment, or imputed for participants who had premature treatment discontinuation. Discontinuations due to sponsor termination of the atacicept 150 mg group were not imputed as flares in this analysis. The BILAG disease activity index evaluates systemic lupus erythematosus (SLE) activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.
Time frame: From screening up to Week 52
Time to First New Flare as Defined by BILAG Score A or B
A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment. Analysis was right-censored at Week 52. The hazard ratios and 95% confidence intervals were obtained from the Cox proportional hazards model. The 25th Percentile of time to new flare was reported using Kaplan-Meier estimates (Median was not reached). The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.
Time frame: From screening up to Week 52
Percentage of Participants Experiencing a New Flare as Defined by BILAG Score A or B During Initial 24 Weeks
A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment, or imputed for participants who had premature treatment discontinuation. The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.
Time frame: From screening up to Week 24
Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares
Ordinal response categories have been defined as: 1) No BILAG A, no BILAG B, and completed treatment, 2) No BILAG A, at least 1 BILAG B during treatment period, and 3) At least 1 BILAG A during treatment period. The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.
Time frame: Week 52
Mean Cumulative Corticosteroid Dose
Time frame: Randomization up to Week 52
| Milestone | Atacicept 75 mg | Atacicept 150 mg | Placebo |
|---|---|---|---|
| Started | 159 | 145 | 157 |
| Treated | 157 | 144 | 154 |
| Completed | 112 | 62 | 111 |
| Not completed | 47 | 83 | 46 |
| Withdrew: Adverse event | 14 | 14 | 18 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 11 | 3 | 14 |
| Withdrew: Protocol violation | 3 | 3 | 2 |
| Withdrew: Death | 0 | 2 | 0 |
| Withdrew: Immunoglobulin less than 3gram per liter | 1 | 0 | 0 |
| Withdrew: Termination of 150 mg group by sponsor | 0 | 55 | 0 |
| Withdrew: Other | 15 | 5 | 9 |
| Withdrew: Randomized but not treated | 2 | 1 | 3 |
A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment, or imputed for participants who had premature treatment discontinuation. Discontinuations due to sponsor termination of the atacicept 150 mg group were not imputed as flares in this analysis. The BILAG disease activity index evaluates systemic lupus erythematosus (SLE) activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.
| percentage of participants | Atacicept 75 mg | Atacicept 150 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or B | 57.32 | 36.11 | 53.25 |
A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment. Analysis was right-censored at Week 52. The hazard ratios and 95% confidence intervals were obtained from the Cox proportional hazards model. The 25th Percentile of time to new flare was reported using Kaplan-Meier estimates (Median was not reached). The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.
| days | Atacicept 75 mg | Atacicept 150 mg | Placebo |
|---|---|---|---|
| Time to First New Flare as Defined by BILAG Score A or B | 143 (112 to 226) | 310 (169 to NA) | 142 (87 to 197) |
A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment, or imputed for participants who had premature treatment discontinuation. The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.
| percentage of participants | Atacicept 75 mg | Atacicept 150 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Experiencing a New Flare as Defined by BILAG Score A or B During Initial 24 Weeks | 40.13 | 28.47 | 35.06 |
Ordinal response categories have been defined as: 1) No BILAG A, no BILAG B, and completed treatment, 2) No BILAG A, at least 1 BILAG B during treatment period, and 3) At least 1 BILAG A during treatment period. The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.
| percentage of participants | Atacicept 75 mg | Atacicept 150 mg | Placebo |
|---|---|---|---|
| No BILAG A, no BILAG B, and completed treatment | 52.3 | 60.5 | 52.9 |
| No BILAG A, at least 1 BILAG B in treatment period | 39.8 | 28.9 | 38.2 |
| At least 1 BILAG A in treatment period | 7.8 | 10.5 | 8.8 |
| mg | Atacicept 75 mg | Atacicept 150 mg | Placebo |
|---|---|---|---|
| Mean Cumulative Corticosteroid Dose | 2456.79 ± 1029.87 | 2018.87 ± 1062.61 | 2624.02 ± 812.44 |
Collected over Baseline up to 76 weeks (end of follow-up of the study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atacicept 75 mg | — | 30/157 (19.1%) | 129/157 (82.2%) |
| Atacicept 150 mg | — | 23/144 (16%) | 120/144 (83.3%) |
| Placebo | — | 27/154 (17.5%) | 118/154 (76.6%) |
| Event | Atacicept 75 mg | Atacicept 150 mg | Placebo |
|---|---|---|---|
| PneumoniaInfections and infestations | 5/157 | 3/144 | 2/154 |
| Upper respiratory tract infectionInfections and infestations | 2/157 | 2/144 | 0/154 |
| Pulmonary alveolar haemorrhageRespiratory, thoracic and mediastinal disorders | 0/157 | 2/144 | 0/154 |
| Urinary tract infectionInfections and infestations | 1/157 | 0/144 | 2/154 |
| Septic shockInfections and infestations | 0/157 | 0/144 | 2/154 |
| Myocardial infarctionCardiac disorders | 1/157 | 0/144 | 2/154 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 0/157 | 0/144 | 2/154 |
| HeadacheNervous system disorders | 0/157 | 0/144 | 2/154 |
| Cervical dysplasiaReproductive system and breast disorders | 0/157 | 0/144 | 2/154 |
| BronchitisInfections and infestations | 2/157 | 0/144 | 0/154 |
| Event | Atacicept 75 mg | Atacicept 150 mg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 31/157 | 17/144 | 23/154 |
| Upper respiratory tract infectionInfections and infestations | 24/157 | 27/144 | 24/154 |
| Urinary tract infectionInfections and infestations | 22/157 | 23/144 | 17/154 |
| Injection site reactionGeneral disorders | 16/157 | 22/144 | 3/154 |
| NasopharyngitisInfections and infestations | 21/157 | 16/144 | 11/154 |
| Injection site erythemaGeneral disorders | 10/157 | 16/144 | 0/154 |
| Back painMusculoskeletal and connective tissue disorders | 14/157 | 5/144 | 8/154 |
| DiarrhoeaGastrointestinal disorders | 9/157 | 5/144 | 13/154 |
| BronchitisInfections and infestations | 12/157 | 12/144 | 6/154 |
| NauseaGastrointestinal disorders | 11/157 | 7/144 | 6/154 |
Intent-to-treat (ITT) population included all the randomized participants, regardless of whether they received treatment.
| Age, Continuous(years) | Atacicept 75 mg | Atacicept 150 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 39.1 ± 12.0 | 39.0 ± 12.8 | 39.0 ± 12.1 | 39.0 ± 12.2 |
| Sex: Female, Male(Participants) | Atacicept 75 mg | Atacicept 150 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 148 | 134 | 148 | 430 |
| Male | 11 | 11 | 9 | 31 |
Showing the first 100 of 113 sites across 29 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2008, a primary completion of Apr 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein
Lupus Erythematosus, Systemic →